4//SEC Filing
BCIP Life Sciences Associates, LP 4
Accession 0000950170-24-137335
CIK 0001936258other
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 5:05 PM ET
Size
41.9 KB
Accession
0000950170-24-137335
Insider Transaction Report
Form 4
Transactions
- Purchase
Pre-Funded Warrant (right to buy)
2024-12-13$24.50/sh+1,632,653$39,999,835→ 1,632,653 total(indirect: See footnotes)Exercise: $0.00From: 2024-12-13→ Ordinary Shares (1,632,653 underlying)
BCLS II Investco (GP), LLC
10% Owner
Transactions
- Purchase
Pre-Funded Warrant (right to buy)
2024-12-13$24.50/sh+1,632,653$39,999,835→ 1,632,653 total(indirect: See footnotes)Exercise: $0.00From: 2024-12-13→ Ordinary Shares (1,632,653 underlying)
BCLS Fund III Investments GP, LLC
10% Owner
Transactions
- Purchase
Pre-Funded Warrant (right to buy)
2024-12-13$24.50/sh+1,632,653$39,999,835→ 1,632,653 total(indirect: See footnotes)Exercise: $0.00From: 2024-12-13→ Ordinary Shares (1,632,653 underlying)
BCLS II Investco, LP
10% Owner
Transactions
- Purchase
Pre-Funded Warrant (right to buy)
2024-12-13$24.50/sh+1,632,653$39,999,835→ 1,632,653 total(indirect: See footnotes)Exercise: $0.00From: 2024-12-13→ Ordinary Shares (1,632,653 underlying)
BCIP Life Sciences Associates, LP
10% Owner
Transactions
- Purchase
Pre-Funded Warrant (right to buy)
2024-12-13$24.50/sh+1,632,653$39,999,835→ 1,632,653 total(indirect: See footnotes)Exercise: $0.00From: 2024-12-13→ Ordinary Shares (1,632,653 underlying)
BCLS Fund III Investments, LP
10% Owner
Transactions
- Purchase
Pre-Funded Warrant (right to buy)
2024-12-13$24.50/sh+1,632,653$39,999,835→ 1,632,653 total(indirect: See footnotes)Exercise: $0.00From: 2024-12-13→ Ordinary Shares (1,632,653 underlying)
Transactions
- Purchase
Pre-Funded Warrant (right to buy)
2024-12-13$24.50/sh+1,632,653$39,999,835→ 1,632,653 total(indirect: See footnotes)Exercise: $0.00From: 2024-12-13→ Ordinary Shares (1,632,653 underlying)
Transactions
- Purchase
Pre-Funded Warrant (right to buy)
2024-12-13$24.50/sh+1,632,653$39,999,835→ 1,632,653 total(indirect: See footnotes)Exercise: $0.00From: 2024-12-13→ Ordinary Shares (1,632,653 underlying)
Transactions
- Purchase
Pre-Funded Warrant (right to buy)
2024-12-13$24.50/sh+1,632,653$39,999,835→ 1,632,653 total(indirect: See footnotes)Exercise: $0.00From: 2024-12-13→ Ordinary Shares (1,632,653 underlying)
Transactions
- Purchase
Pre-Funded Warrant (right to buy)
2024-12-13$24.50/sh+1,632,653$39,999,835→ 1,632,653 total(indirect: See footnotes)Exercise: $0.00From: 2024-12-13→ Ordinary Shares (1,632,653 underlying)
Footnotes (6)
- [F1]Represents a pre-funded warrant to purchase 1,257,141 Ordinary Shares and a pre-funded warrant to purchase 375,512 Ordinary Shares, purchased by Bain Capital Life Sciences Opportunities III, LP ("BCLS Fund III Opportunities") and BCLS II Equity Opportunities, LP ("BCLS Fund II Opportunities"), respectively, in an underwritten public offering.
- [F2]The pre-funded warrants cannot be exercised if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated with the holder for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of Ordinary Shares then outstanding immediately following such exercise.
- [F3]The pre-funded warrants do not expire.
- [F4]Bain Capital Life Sciences III General Partner, LLC ("BCLS III GP") is the general partner of Bain Capital Life Sciences Fund III, L.P. ("BCLS III"), which is the sole member of Bain Capital Life Sciences Opportunities III GP, LLC ("BCLS Fund III Opportunities GP"), which is the general partner of BCLS Fund III Opportunities. As a result, each of BCLS III GP and BCLS III may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund III Opportunities. Each of BCLS III GP and BCLS III disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
- [F5]Bain Capital Life Sciences Investors II, LLC ("BCLSI II") is the general partner of Bain Capital Life Sciences Fund II, L.P. ("BCLS Fund II"), which is the manager of BCLS II Equity Opportunities GP, LLC, which is the general partner of BCLS Fund II Opportunities. As a result, each of BCLSI II and BCLS Fund II may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund II Opportunities. Each of BCLSI II and BCLS Fund II disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
- [F6]Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of each of BCLS III GP and BCLSI II. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by each of BCLS Fund III Opportunities and BCLS Fund II Opportunities. BCLSI disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Documents
Issuer
NewAmsterdam Pharma Co N.V.
CIK 0001936258
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001702921
Filing Metadata
- Form type
- 4
- Filed
- Dec 16, 7:00 PM ET
- Accepted
- Dec 17, 5:05 PM ET
- Size
- 41.9 KB